News coverage about Grifols SA, Barcelona (NASDAQ:GRFS) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Grifols SA, Barcelona earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.436699633744 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:
- Grifols SA, Barcelona (GRFS) Upgraded to Buy by BidaskClub (americanbankingnews.com)
- Estimating The Fair Value Of Grifols SA. (BME:GRF) (finance.yahoo.com)
- Grifols SA, Barcelona (GRFS) Given Consensus Recommendation of “Hold” by Brokerages (americanbankingnews.com)
- Grifols SA, Barcelona (GRFS) Upgraded to Buy at ValuEngine (americanbankingnews.com)
- Grifols SA, Barcelona (GRFS) Stock Rating Lowered by BidaskClub (americanbankingnews.com)
A number of equities analysts have weighed in on GRFS shares. BidaskClub cut shares of Grifols SA, Barcelona from a “hold” rating to a “sell” rating in a research report on Wednesday, February 28th. Morgan Stanley dropped their price objective on shares of Grifols SA, Barcelona from $23.00 to $22.00 and set an “underweight” rating for the company in a report on Thursday, March 1st. HSBC raised shares of Grifols SA, Barcelona from a “reduce” rating to a “hold” rating in a research note on Wednesday, March 14th. Zacks Investment Research raised shares of Grifols SA, Barcelona from a “sell” rating to a “hold” rating in a research note on Thursday, January 4th. Finally, ValuEngine raised shares of Grifols SA, Barcelona from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. Three analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $22.50.
About Grifols SA, Barcelona
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with MarketBeat.com's FREE daily email newsletter.